Sjögren's disease & overlap diseases
Serum CCL28 as a biomarker for diagnosis and evaluation of Sjögren’s syndrome
Authors' conclusion
Serum CCL28 is a useful biomarker in the diagnosis and evaluation of SS.
Study context
- Population
- Patients with Sjögren's syndrome (SS), rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and healthy controls
- Exposure
- Serum CCL28 in SS vs RA, SLE and healthy controls
- Outcome
- Serum CCL28 levels
Methodological detailscase-control, GEO database analysis, ELISA
- Case-control
- GEO database analysis
- ELISA
Main finding
As reported in the abstract
- Serum CCL28 significantly lower in both primary and secondary SS than in healthy controls (HCs)
- No significant differences between RA or SLE and HCs
- Serum CCL28 dramatically lower in SS secondary to RA or SLE than in RA and SLE alone
Observational data: associations, not effects.
Further findings
CCL28 mRNA in salivary glands (GEO database)
- Decreased in SS, accompanying more severe pathological injury
Correlations of serum CCL28
- No remarkable correlation with serum immunoglobulin A (IgA)
- Labial salivary gland (LSG) focus score negatively correlated with serum CCL28
Serum CCL28 in SS subsets
- Lower in SS with dental caries and thrombocytopenia
Original publication
Serum CCL28 as a biomarker for diagnosis and evaluation of Sjögren’s syndrome. Scand J Rheumatol. Published 20 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →